Y
Young Kwang Chae
Researcher at Northwestern University
Publications - 258
Citations - 7630
Young Kwang Chae is an academic researcher from Northwestern University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 39, co-authored 192 publications receiving 4972 citations. Previous affiliations of Young Kwang Chae include Johns Hopkins University School of Medicine & Yeshiva University.
Papers
More filters
Journal ArticleDOI
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Robert C. Doebele,Alexander Drilon,Alexander Drilon,Luis Paz-Ares,Salvatore Siena,Alice T. Shaw,Anna F. Farago,Collin M. Blakely,Takashi Seto,Byung Chul Cho,D. Tosi,Benjamin Besse,Sant P. Chawla,Lyudmila Bazhenova,John C. Krauss,Young Kwang Chae,Minal A. Barve,Ignacio Garrido-Laguna,Stephen V. Liu,Paul Conkling,Thomas John,Marwan Fakih,Darren Sigal,Herbert H. Loong,Gary L Buchschacher,Pilar Garrido,Jorge Nieva,Conor E. Steuer,Tobias Overbeck,Daniel W. Bowles,Elizabeth Fox,Todd Riehl,Edna Chow-Maneval,B. Simmons,Na Cui,Ann M. Johnson,Susan Eng,Timothy R. Wilson,George D. Demetri +38 more
TL;DR: Results show that entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile.
Journal ArticleDOI
Wnt/beta-catenin pathway: modulating anticancer immune response.
Sachin Gopalkrishna Pai,Sachin Gopalkrishna Pai,Benedito A. Carneiro,Jose Mauricio Mota,Ricardo Costa,Caio Abner Leite,Romualdo Barroso-Sousa,Jason B. Kaplan,Young Kwang Chae,Francis J. Giles +9 more
TL;DR: The role of Wnt/β-catenin pathway in cancer and ongoing therapeutic strategies involving this pathway are summarized to highlight its potential impact on responses to immunotherapy treatments.
Journal ArticleDOI
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae,Ayush Arya,Wade T. Iams,Marcelo Rocha Cruz,Sunandana Chandra,Jaehyuk Choi,Francis J. Giles +6 more
TL;DR: The current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC) is summarized and a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies is presented.
Journal ArticleDOI
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon,Alexander Drilon,Salvatore Siena,Rafal Dziadziuszko,Fabrice Barlesi,Matthew G Krebs,Alice T. Shaw,Filippo de Braud,Christian Rolfo,Myung-Ju Ahn,Jürgen Wolf,Takashi Seto,Byoung Chul Cho,Manish R. Patel,Chao Hua Chiu,Thomas John,Koichi Goto,Christos S. Karapetis,Hendrick Tobias Arkenau,Sang We Kim,Yuichiro Ohe,Yu Chung Li,Young Kwang Chae,Christine H. Chung,Gregory A. Otterson,Haruyasu Murakami,Chia-Chi Lin,Daniel Shao-Weng Tan,Hans Prenen,Todd Riehl,Edna Chow-Maneval,B. Simmons,Na Cui,Ann D. Johnson,Susan Eng,Timothy R. Wilson,Robert C. Doebele +36 more
TL;DR: Entrectinib is active with durable disease control in patients with ROS1 fusion-positive NSCLC, and is well tolerated with a manageable safety profile, making it amenable to long-term dosing in these patients.
Journal ArticleDOI
Repurposing metformin for cancer treatment: current clinical studies
Young Kwang Chae,Ayush Arya,Mary-Kate Malecek,Daniel Sanghoon Shin,Benedito A. Carneiro,Sunandana Chandra,Jason B. Kaplan,Aparna Kalyan,Jessica K. Altman,Leonidas C. Platanias,Francis J. Giles +10 more
TL;DR: The role of metformin as a potential cancer treatment is reviewed to critically review the results of a small number of completed trials.